US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

GeoVax Labs Inc

0.0329

-0.0070-17.54%

Volume:52.75K

Turnover:1.60K

Market Cap:- -

PE:- -

High:0.0400

Open:0.0400

Low:0.0300

Close:0.0399

Loading ...

Overview Company News Filings

GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs

GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative

Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability

GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial

GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024

GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025

GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent

THOMSON REUTERS

BRIEF-Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia

THOMSON REUTERS

GeoVax Labs Inc - Dsmb Recommends Continuation of Geo-Cm04s1 Vaccine Trial

THOMSON REUTERS

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

THOMSON REUTERS

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GOVXW/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GOVXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","market":"US","secType":"STK","nameCN":"GeoVax Labs Inc","latestPrice":0.0329,"timestamp":1745870400000,"preClose":0.0399,"halted":0,"volume":52752,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-Mkt","change":-0.007,"latestTime":"04-29 07:56:59 EDT","open":0.04,"high":0.04,"low":0.03,"amount":1598.3026,"amplitude":0.250627,"askPrice":0,"askSize":0,"bidPrice":0.0272,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745933400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.03,"volumeRatio":3.03256070117177},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","floatShares":0,"roa":"-180.23%","roe":"-462.31%","lyrEps":0,"volumeRatio":3.03256070117177,"shares":0,"dividePrice":0,"high":0.04,"amplitude":0.250627,"preClose":0.0399,"low":0.03,"week52Low":0.0268,"pbRate":"0.00","psRate":"0.00","week52High":0.65,"institutionHeld":0,"latestPrice":0.0329,"committee":1,"eps":0,"divideRate":0,"volume":52752,"delay":0,"ttmEps":0,"open":0.04,"prevYearClose":0.1001,"prevWeekClose":0.0399,"prevMonthClose":0.0502,"prevQuarterClose":0.0502,"fiveDayClose":0.0333,"twentyDayClose":0.0503,"sixtyDayClose":0.1044},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GOVXW\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510638246","title":"GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2510638246","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510638246?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:00","pubTimestamp":1739282400,"startTime":"0","endTime":"0","summary":"Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide. ATLANTA, GA - February 11, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, proudly congratulates Dr. Valerie Montgomery Rice, President and CEO of Morehouse School of Medicine, on being honored with the 2025 Healthcare Champions Lifetime Achievement Award by the Atlanta Business Chronicle. This prestigious award recognizes Dr. Montgomery Rice's exceptional contributions to healthcare and her unwavering commitment to advancing health equity, particularly among underserved and minority populations globally.In December 2022, Dr. Montgomery Rice joined GeoVax as a Special Advisor to the Chairman, CEO, and Board of Directors. Her expertise has been invaluable in guiding the Company's mission to develop innovative vaccines and immunotherapies that address the needs of underserved populations.GeoVa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-congratulates-dr-valerie-montgomery-140000050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4137","BK4548","GOVXW","LCUT","BK4568","BNTX","HCSG","R","BK4022","BK4180","BK4551","BK4535","BK4139","GOVX","BK4232","BK4585"],"gpt_icon":0},{"id":"2509281733","title":"GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2509281733","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509281733?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:00","pubTimestamp":1738764000,"startTime":"0","endTime":"0","summary":"Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum. GEO-CM04S1 continues to demonstrate potential for both immunocompromised patients and as a booster vaccine for those previously inoculated with mRNA vaccines. In 2025, the Company anticipates completion of the evaluation trial among Chronic Lymphocytic Leukemia  patients, a patient population recognized to currently have minimal COVID-19 vaccine options. Interim data reported in Q4 2024 suggest GEO-CM04S1 may offer superior immune responses to CLL patients compared to an mRNA vaccine.GeoVax also expects to report final results from its healthy adults booster trial, offering valuable data on the vaccine's safety and immunogenicity profile. Another pivotal milestone for GEO-CM04S1 in 2025 is the anticipated initiation of patient enrollment in the BARDA-funded Project NextGen Phase 2b trial, which will evaluate GEO-CM04S1 compared to an authorized mRNA vaccine within a 10,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-anticipates-significant-2025-progress-140000731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4588","GOVX","BK4548","GOVXW","BK4139","PRGS","BNTX","BK4585","BK4535","R","BK4232","BK4097","BK4551","LU2065732104.USD","BK4022"],"gpt_icon":0},{"id":"2508452379","title":"GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the  2025 BIO CEO & Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2508452379","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508452379?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:00","pubTimestamp":1738677600,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - February 4, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present GeoVax's 2025 strategic vision and milestones at the 2025 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 10-12, 2025.GeoVax senior management will also conduct one-on-one meetings throughout the conference. For more information or to schedule a meeting, please visit the conference page here or contact GeoVax Investor Relations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-showcase-advancements-vaccines-immunotherapies-140000253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4585","LU1169590202.USD","LU1169589451.USD","R","BK4022","BK4588","BK4568","GOVXW","BNTX","BK4232","BK4551","BIO","BK4139","GOVX","BK4121","BK4548"],"gpt_icon":0},{"id":"2508314656","title":"GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2508314656","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508314656?lang=en_us&edition=fundamental","pubTime":"2025-02-03 22:00","pubTimestamp":1738591200,"startTime":"0","endTime":"0","summary":"Harnessing AI to Revolutionize Vaccine and Therapy Development. ATLANTA, GA - February 3, 2025  - GeoVax Labs, Inc. , a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J. Trump's Stargate Initiative, which aims to harness advanced technologies including Artificial Intelligence  to strengthen U.S. healthcare, biosecurity, and global innovation leadership. This announcement aligns with GeoVax's commitment to leveraging AI across its vaccine and cancer immunotherapy programs to accelerate research, optimize operations, and deliver life-saving solutions.GeoVax has embedded AI into its platforms for vaccine development and cancer immunotherapy, enabling groundbreaking advances:. Vaccine Development: AI drives target discovery and design for vaccines using the Modified Vaccinia Ankara  platform, including GEO-CM04S1, GeoVax's next-generation vaccine for COVID-19, and vaccines for Mpox and Smallpox. AI predicts pathogen mutations, ensuring ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-announces-strategic-integration-ai-140000457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BNTX","BK4022","BK4583","BK4139","BK4551","BK4548","BK4568","GOVX","GOVXW","BK4232","BK4535","BK4588","R"],"gpt_icon":0},{"id":"2507663991","title":"Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663991","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663991?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:00","pubTimestamp":1738159200,"startTime":"0","endTime":"0","summary":"Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness. ATLANTA, GA - January 29, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies, today highlighted that it is committed to playing a pivotal role in reinforcing America's biosecurity through its GEO-MVA vaccine, designed to combat both smallpox and Mpox. In light of recent global health challenges, the United States has recognized the critical need to reduce dependence on foreign vaccine suppliers and bolster domestic production capabilities.The 2022 Mpox pandemic significantly depleted the U.S. Strategic National Stockpile  of vaccines, exposing vulnerabilities in the nation's preparedness for emerging health threats. Compounding this issue is the nation's reliance on a single foreign manufacturer for smallpox and Mpox vaccines. This dependency poses a strategic risk, especially considering the current Clade I Mpox outbreak in Africa, characterized","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strengthening-americas-biosecurity-geovax-advances-140000132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4232","BK4568","BK4585","BIO","GOVXW","R","BK4535","BK4139","LU1169589451.USD","LU1169590202.USD","BK4548","BK4588","BK4551","BK4121","BNTX","BK4583","GOVX"],"gpt_icon":0},{"id":"2506370421","title":"GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2506370421","media":"NewMediaWire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506370421?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:00","pubTimestamp":1737986400,"startTime":"0","endTime":"0","summary":"Process Expected to Increase Production Yield, Flexibility at Lower Cost. ATLANTA, GA - January 27, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has shared updates about its development-stage advanced Modified Vaccinia Ankara  vaccine manufacturing process. This anticipated process provides the potential to not only address today's pressing health challenges but also paves the way for more efficient, flexible and lower-cost MVA-vaccine manufacturing.The MVA platform is uniquely designed to incorporate multiple antigens into a single vaccine. This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine, the MVA platform offers distinct advantages, including:. Protection against diseases such as Mpox and smallpox.This advanced MVA manufacturing process is expected to significantly simplify vaccine p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-advanced-mva-manufacturing-process-140000479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4548","BK4022","BK4539","BK4157","BK4139","GOVX","BK4561","AEIS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4568","GOVXW","BK4097","BK4232","BK4560","R","CEF","BK4551","S","BK4585","BNTX","IE0031619046.USD","BK4588","LU2286300806.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2503644020","title":"GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503644020","media":"NewMediaWire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503644020?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:00","pubTimestamp":1736949600,"startTime":"0","endTime":"0","summary":"Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy. ATLANTA, GA - January 15, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing innovative immunotherapies and vaccines for cancer and infectious diseases, announced significant progress in advancing Gedeptin as a cancer therapy. Gedeptin, based on a Gene-Directed Enzyme Prodrug Therapy  platform, employs a targeted approach to deliver therapeutic agents directly to tumor sites. The result of this approach is the localized production of a potent anti-cancer agent within the tumor microenvironment, while minimizing systemic exposure and the potential for associated side effects.Following a review of the data from the completed Phase 1 single-cycle and Phase 1/2 multi-cycle Gedeptin trials among patients with advanced Head & Neck (H&N) tumors, GeoVax has decided to initiate a Phase 2 clinical study, evaluating neoadjuvant Gedeptin therapy in combination with an approved immune check","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-announces-major-gedeptin-milestone-140000168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4535","BK4551","GOVX","BK4568","GOVXW","BK4585","BK4232","BK4022","BK4588","R","BNTX","BK4139","BK4583"],"gpt_icon":0},{"id":"2503888725","title":"GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2503888725","media":"NewMediaWire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503888725?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:00","pubTimestamp":1736776800,"startTime":"0","endTime":"0","summary":"Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients. ATLANTA, GA - January 13, 2025  - GeoVax Labs, Inc. , a biotechnology company specializing in immunotherapies and vaccines against infectious diseases and cancers, is pleased to announce substantial progress in the clinical development of its COVID-19 vaccine portfolio during 2024. These achievements underscore the potential of GEO-CM04S1 to address critical public health needs, particularly among immunocompromised populations.In June 2024, GeoVax received a significant award through the Rapid Response Partnership Vehicle , funded by the Biomedical Advanced Research and Development Authority  as part of PNG. This award supports a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 compared to an approved COVID-19 vaccine. The study is set to commence in the second half of 2025, with Allucent, a global clinical researc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-achieves-significant-progress-next-140000313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU2286300806.USD","PRGS","R","BK4560","GOVX","BK4588","BK4535","BK4548","BK4585","BK4561","S","BK4139","BK4539","BK4022","GOVXW","BK4232","LU2065732104.USD","BK4551","BNTX","BK4097"],"gpt_icon":0},{"id":"2501778190","title":"GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501778190","media":"NewMediaWire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501778190?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:00","pubTimestamp":1736344800,"startTime":"0","endTime":"0","summary":"Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin  and GEO-MVA . ATLANTA, GA - January 8, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held January 15-16, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman and CEO, David Dodd, in real time.Mr. Dodd will be presenting at 2:35 pm ET on Thursday, January 16, 2025, reviewing the Company's 2024 progress. Following his presentation, Mr. Dodd will open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr. Dodd will do his best to get through as many of them ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-review-2024-progress-emerging-140000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4588","GOVX","BK4548","GOVXW","BK4139","PRGS","BK4583","BK4585","BK4535","BNTX","BK4232","BK4097","BK4551","R","LU2065732104.USD","BK4022"],"gpt_icon":0},{"id":"2501523732","title":"GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501523732","media":"NewMediaWire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501523732?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:00","pubTimestamp":1736172000,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - January 6, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will review 2024 progress in a presentation at the Biotech Showcase coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025.Hilton Union Square, 333 O'Farrell Street, Yosemite A , San Francisco, CA. A live webcast of the presentation will be available here. A replay will be available approximately 2 hours after the presentation and accessible for three months. Additionally, senior management of GeoVax will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. One-on-one appointments may be requested as follows:. Through the Biotechnology Innovation Organization  partnering platform here.Direct outreach to the Company at info@geovax.com or to Precision AQ at maxmilian.gadick","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-review-2024-progress-biotech-140000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0106831901.USD","LU0314104364.USD","LU1720051017.SGD","BK4121","LU1668664300.SGD","BK4548","BK4535","LU1169590202.USD","BK4097","LU1989772840.SGD","IE00BKVL7J92.USD","BIO","BK4585","LU1989772923.USD","LU1548497426.USD","LU2111349929.HKD","LU2347655156.SGD","GOVX","BK4232","BK4551","HCSG","IE00BZ1G4Q59.USD","LU0795875169.SGD","PRGS","BK4139","BK4534","BK4588","LU2028103732.USD","LU2271345857.HKD","R","BK4127","LU0225283273.USD","LU2089284900.SGD","LU0158827781.USD","LU0267386448.USD","LU0320765646.SGD","BK4516","LU1074936037.SGD","LU2065732104.USD","LU0006306889.USD","LU0912757837.SGD","LU1720051108.HKD","BNTX","BK4568","LU2089283258.USD","LU1162221912.USD","BK4583","LU0158827948.USD","GOVXW","LU1732799900.SGD","LU0098860793.USD"],"gpt_icon":0},{"id":"2490904720","title":"GeoVax Receives Notice of Allowance for Cancer Vaccine Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2490904720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490904720?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:00","pubTimestamp":1733752802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUA24D9PC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","GOVXW","GOVX","BK4139"],"gpt_icon":0},{"id":"2484940606","title":"BRIEF-Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2484940606","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484940606?lang=en_us&edition=fundamental","pubTime":"2024-11-19 22:29","pubTimestamp":1732026595,"startTime":"0","endTime":"0","summary":"Nov 19  - GeoVax Labs Inc   :   * GEOVAX ANNOUNCES POSITIVE INTERIM DATA REVIEW FOR PHASE 2 CLINICAL TRIAL OF COVID-19 VACCINE BOOSTER IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA   * GEOVAX LABS INC - DSMB RECOMMENDS CONTINUATION OF GEO-CM04S1 VACCINE TRIALSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GOVXW","BK4583","GOVX","BK4139"],"gpt_icon":0},{"id":"2484942280","title":"GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2484942280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484942280?lang=en_us&edition=fundamental","pubTime":"2024-11-19 22:00","pubTimestamp":1732024801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUAS7JTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4139","GOVX","GOVXW"],"gpt_icon":0},{"id":"2484942212","title":"GeoVax Labs Inc - Dsmb Recommends Continuation of Geo-Cm04s1 Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484942212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484942212?lang=en_us&edition=fundamental","pubTime":"2024-11-19 22:00","pubTimestamp":1732024801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUAS7JTY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GOVX","BK4583","GOVXW","BK4139"],"gpt_icon":0},{"id":"2484882947","title":"GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2484882947","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484882947?lang=en_us&edition=fundamental","pubTime":"2024-11-19 22:00","pubTimestamp":1732024800,"startTime":"0","endTime":"0","summary":"ATLANTA, Nov. 19, 2024  -- GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board  for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia .Dodd continued, “This ongoing trial is providing important information about the potential use of GEO-CM04S1 in one of many immune-compromised patient populations. It is also complementary to the pending star","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/h0RiYxJ897k8ZXUNgAGw7g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f4b68bb959a14b627abc085244280dc8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/h0RiYxJ897k8ZXUNgAGw7g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f4b68bb959a14b627abc085244280dc8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-announces-positive-interim-data-140000167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","BK4588","GOVXW","GOVX","BK4539","BNTX","BK4560","BK4551","BK4535","LU2286300806.USD","BK4097","BK4568","S","BK4561","BK4548"],"gpt_icon":1},{"id":"2483152023","title":"Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2483152023","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483152023?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:16","pubTimestamp":1731482207,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Geovax Labs Inc  received a significant BARDA Project NextGen Award valued at almost $400 million, supporting a 10,000 patient comparative trial.The company is advancing its vaccine candidate against monkeypox and smallpox, with production of the first CGMP clinical substance batch underway.The company is actively pursuing business partnerships and collaborations for worldwide development and commercialization.There is uncertainty regarding the timing of regulatory approvals and the ability to meet expedited pathways for its vaccine candidates.The company is dependent on successful partnerships and collaborations to achieve its commercialization and distribution goals.GuruFocus has detected 3 Warning Signs with GOVX.Q: What progress has been made in seeking an expedited regulatory pathway for the OX vaccine, and when will the 10,000-patient Phase 2 COVID trial start enrolling?A: John Sha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/brzX0XaRQsHyWbliDqCBHQ--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/9b4bc86731606105ea5aebfb6a7231cb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/brzX0XaRQsHyWbliDqCBHQ--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/9b4bc86731606105ea5aebfb6a7231cb"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-labs-inc-govx-q3-071647922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVXW","GOVX"],"gpt_icon":1},{"id":"2481250238","title":"GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481250238","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481250238?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA6N5SWG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GOVX","BK4139","BK4583","GOVXW"],"gpt_icon":0},{"id":"2481507847","title":"GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507847?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"ATLANTA, Nov. 05, 2024  -- GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/h0RiYxJ897k8ZXUNgAGw7g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f4b68bb959a14b627abc085244280dc8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/h0RiYxJ897k8ZXUNgAGw7g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f4b68bb959a14b627abc085244280dc8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-report-third-quarter-2024-140000363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTX","BK4139","GOVX","BK4568","GOVXW","BK4588","BK4535","BK4548","BK4551","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GOVXW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-08-03","symbol":"GOVXW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659499200000,"reportTimeType":"post","actualEps":null},{"date":"2022-04-27","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1651089600000,"name":null,"time":"Post Market","dateTimestamp":1651032000000,"actualEps":null},{"date":"2022-03-09","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1646859600000,"name":null,"time":"Post Market","dateTimestamp":1646802000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GOVXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GOVXW\",market:\"US\",delay:false,,,undefined,":{}}}